InvestorsHub Logo
Boards
News
Market Data
Markets
Discover
Discover
Subscribe Login/Register
S&P 500
5,321.41
(
0.25%
)
US TECH 100
18,244.80
(
0.27%
)
Dow Jones
39,872.99
(
0.17%
)
Brent Oil
82.16
(
-0.35%
)
Bitcoin
69,817.96
(
-0.45%
)
Post# of 251888
Next 10
Reply Private New
Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

DewDiligence

Send PM Follow Ignore
Followers 829
Posts 119670
Boards Moderated 16
Alias Born 09/05/2002

DewDiligence

Member Level

Re: None

Monday, 02/08/2021 8:07:49 PM

Monday, February 08, 2021 8:07:49 PM

Post# of 251888
BMY—Opdivo monotherapy shows statsig-superior DFS to placebo in adjuvant MIUC*:

https://finance.yahoo.com/news/adjuvant-treatment-opdivo-nivolumab-demonstrates-220000022.html

CHECKMATE-274 is the first phase-3 immunotherapy trial to show a clinical benefit in this setting. The HR for DFS was 0.70 in the overall trial and 0.53 in the subgroup with PD-L1>=1% (p<0.001 for both results).

*Muscle-Invasive Urothelial Carcinoma.

“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”

Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Last Read Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.

Sign Up